Kasvu Therapeutics Raises €30 Million to Advance Novel TrkB-Targeting Depression Drug Candidate KTX-0141 Toward Human Trials
(IN BRIEF) Kasvu Therapeutics, a University of Helsinki spinout, has raised €30 million to advance KTX-0141, a preclinical drug candidate for major depressive disorder, toward first-in-human studies that could begin as early as summer 2027. The financing, led by Hadean … Read the full press release →
More from Commercial newswire
- BASF Ultramid® B3K Enables BOOXit Reusable Transport Boxes for Automated, Digitally Connected Logistics
- Telekom and Unikie Demonstrate Automated Rail Loading at Audi Ingolstadt Plant to Advance End-to-End Vehicle Logistics
- Siemens Mobility and Infrabel Sign €215 Million Framework Agreement to Modernize Belgium’s Rail Operational Control Systems Over 11 Years
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →